GRI Bio Announces Pricing of Public Offering
LA JOLLA, CA, April 01, 2025 – GRI Bio, Inc. (GRI), a pioneering biotechnology company specializing in the development of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic, and autoimmune diseases, recently announced the pricing of a public offering. The offering includes the sale of common stock and various types of warrants.
Details of the Offering
According to the press release, GRI will sell an aggregate of 1,388,888 shares of common stock (or common stock equivalents) along with Series E-1, E-2, and E-3 warrants. The Series E-1 warrants will allow the purchasers to buy an additional 1,388,888 shares of common stock, while the short-term Series E-2 and E-3 warrants will grant the right to purchase 1,388,888 shares of common stock each. The combined price for one share of common stock and the accompanying warrant will be $3.60.
Exercise Prices and Expiration Dates
The Series E-1 warrants will have an exercise price of $3.20 per share and will remain valid until the five-year anniversary of the initial issuance date. The short-term Series E-2 warrants will expire on the eighteen-month anniversary of the initial issuance date, while the short-term Series E-3 warrants will terminate on the nine-month anniversary.
Impact on Investors
For potential investors, this public offering presents an opportunity to invest in a biotechnology company focusing on innovative treatments for various diseases. By purchasing shares and accompanying warrants, investors could benefit from potential stock price appreciation and the right to buy additional shares at a discounted price if they choose to exercise their warrants.
Impact on the World
The advancement of NKT cell modulators for the treatment of inflammatory, fibrotic, and autoimmune diseases could have a significant impact on the global healthcare landscape. If successful, GRI Bio’s treatments could provide relief to millions of people suffering from these conditions. Moreover, the development of these therapies could lead to new opportunities for researchers and investors in the biotechnology sector.
Conclusion
GRI Bio’s announcement of the pricing of its public offering represents an exciting development for the biotechnology industry and potential investors. With a focus on innovative treatments for various diseases, GRI Bio’s advancements in NKT cell modulators could lead to significant improvements in healthcare and create new opportunities for growth in the sector.
- GRI Bio announces public offering of common stock and various types of warrants
- Combined price for one share and the accompanying warrant is $3.60
- Series E-1 warrants have a five-year expiration date
- Short-term Series E-2 and E-3 warrants will expire in 18 months and 9 months, respectively
- Investors can benefit from potential stock price appreciation and the right to buy additional shares at a discounted price
- GRI Bio’s advancements in NKT cell modulators could lead to significant improvements in healthcare and create new opportunities for growth in the biotechnology sector
